The Centers for Medicaid and Medicare Services’ controversial decision to restrict Medicare coverage for Alzheimer’s drugs has prompted interest among congressional Republicans for more clarity on Medicare’s “reasonable and necessary” coverage standard. It has also raised concerns that trouble ensues when CMS makes a decision that appears to second guess the US Food and Drug Administration.
CMS released a final national coverage determination in April that declares Medicare coverage for monoclonal antibodies for Alzheimer’s disease will...








